Literature DB >> 23887583

Thomas Hodgkin: the "man" and "his disease": humani nihil a se alienum putabit (nothing human was foreign to him).

Stephen A Geller1, Clive R Taylor.   

Abstract

Thomas Hodgkin (1798-1865) was one of the leading physicians and scientists of the nineteenth century. A renowned diagnostician, he carried out pioneering work in public health, but devoted the greater part of his career to the study of pathology. His contributions transcend many fields, medical and non-medical, but his most important legacy to medical science was the recognition of the disease that bears his name. The diagnosis of Hodgkin's disease was difficult pending recognition of the "peculiar giant cells" that came to characterize the diagnosis. With identification of the Reed-Sternberg cell, it might have been expected that debate concerning the nature of Hodgkin's disease would be stilled. History proved to the contrary. A fierce controversy ignited with respect to the cellular origin of the Reed-Sternberg cell and the relationship, if any, of Hodgkin's disease to other malignant processes arising in the "absorbent glands and spleen." For a century, arguments ebbed and flowed, reflective of individual opinions and changing concepts, yielding ultimately to new methods for examining and identifying cells.

Entities:  

Mesh:

Year:  2013        PMID: 23887583     DOI: 10.1007/s00428-013-1442-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  40 in total

1.  Thomas Hodgkin (1798-1866): pathologist, social scientist, and philanthropist.

Authors:  A R Zantinga; M J Coppes
Journal:  Med Pediatr Oncol       Date:  1996-08

2.  On some Morbid Appearances of the Absorbent Glands and Spleen.

Authors: 
Journal:  Med Chir Trans       Date:  1832

3.  Thomas Hodgkin 1798-1866.

Authors:  C Hardwick
Journal:  Guys Hosp Rep       Date:  1966

4.  Thomas Hodgkin, physician and social scientist.

Authors:  E H Kass
Journal:  Guys Hosp Rep       Date:  1966

5.  Thomas Hodgkin (1798-1866).

Authors:  K Aterman
Journal:  Am J Dermatopathol       Date:  1986-04       Impact factor: 1.533

6.  Doctors afield. Martin Delany, Thomas Hodgkin, and the Black Nationalist movement.

Authors:  A M Kass; E H Kass
Journal:  N Engl J Med       Date:  1981-09-17       Impact factor: 91.245

7.  A history of the Reed-Sternberg cell.

Authors:  C R Taylor
Journal:  Biomedicine       Date:  1978 Jul-Aug

Review 8.  Classifications of lymphoma; reflections of time and technology.

Authors:  Clive R Taylor; Robert J Hartsock
Journal:  Virchows Arch       Date:  2011-04-19       Impact factor: 4.064

9.  Thomas Hodgkin and Hodgkin's disease. Two paradigms appropriate to medicine today.

Authors:  S Hellman
Journal:  JAMA       Date:  1991-02-27       Impact factor: 56.272

10.  Dr Thomas Hodgkin and Sir Moses Montefiore Bart--the friendship of two remarkable men.

Authors:  A Sakula
Journal:  J R Soc Med       Date:  1979-05       Impact factor: 18.000

View more
  3 in total

1.  The Legacy of Thomas Hodgkin Is Still Relevant 150 Years After His Death. Nothing of Humanity Was Foreign to Him.

Authors:  Eldad J Dann
Journal:  Rambam Maimonides Med J       Date:  2017-01-30

2.  Applicability of protocols from high-income countries in a resource limited setting; real world data of histopathology, clinical features and long-term outcome of Hodgkin Lymphoma in Sri Lanka.

Authors:  Saman Hewamana; Lakmali Kandabadage; Thurairajah Skandarajah; Natasha Peiris; Sobitha Abeyaratne; Gehan Arseculeratne; Eranga Perera; Mahesh Harischandra; Ananda Wijewickrama; Gnani Somasundaram; Vadivelu Srinivasan; Surjit Somiah; Priyankara Jayawardena; Rohini Wadanamby; Geethani Galagoda; Chathuri Jayasinghe; Chandu De Silva; Sanjeewa Munasinghe; Bandula Wijesiriwardena; Jayantha Balawardena
Journal:  EClinicalMedicine       Date:  2021-07-06

3.  Overview and outcome of Hodgkin's Lymphoma: Experience of a single developing country's oncology centre.

Authors:  Rawand P Shamoon; Mohamad Dahir Ali; Nazar P Shabila
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.